首页> 外文OA文献 >Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study

【2h】

Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study

机译：长期治疗的功效与一次性类风湿性关节炎患者曾经 - 每日生长in 2毫克：后HOC分析24周，第三期，随机，受控研究和一个长期扩展研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Alvin F. Wells; Bochao Jia; Li Xie; Guillermo J. Valenzuela; Edward C. Keystone; Zhanguo Li; Amanda K. Quebe; Kirstin Griffing; Susan Otawa; Boulos Haraoui;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial [J] . Bingham Clifton O. III, Mendelsohn Alan M., Kim Lilianne, Arthritis care & research . 2015 ,第12期

机译：尽管采用甲氨蝶呤治疗，但活动性类风湿关节炎患者采用静脉Golimumab治疗维持临床和放射学获益：III期，双盲，随机，安慰剂对照的开放标签长期延长的112周疗效和安全性结果试用版
2. Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study [J] . Yue Yang, Jianhua Xu, Jian Xu, Therapeutic advances in musculoskeletal disease. . 2021 ,第a期

机译：患者报告从随机，双盲，安慰剂控制的结果，对患者的患者的患者患者的AICA III研究，以严重活跃的类风湿性关节炎和对甲氨蝶呤治疗的反应不足：RA-BALLAGE研究结果
3. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study [J] . Min-Chan Park, Hiroaki Matsuno, Jinseok Kim, Arthritis research & therapy. . 2019 ,第1期

机译：使用依那西普生物仿制药（LBEC0101）或从参比依那西普改用LBEC0101对类风湿关节炎患者的长期疗效，安全性和免疫原性：III期多中心，随机，双盲，平行组研究的开放标签扩展
4. Efficacy Analysis of Preservative-Free Tafluprost and Timolol in Open-Angle Glaucoma and OHT Patients in a Phase-III Study [C] . GrundenJ., Lupinacci R. International Symposium on Ocular Pharmacology and Therapeutics . 2013

机译：在第三阶段研究中，在开放角度荧光眼和OHT患者中无防腐型TaFluprost和蒂莫尔的疗效分析
5. Utilization of Propensity Score Weighting and Targeted Maximum Likelihood Estimation in the Post Hoc Analysis of a Randomized Controlled Trial for the Treatment of Cocaine Dependence (NIDA-MDS-Modafinil-0001) [D] . Shan, Weiwei. 2018

机译：倾向评分加权和目标最大似然估计在可卡因依赖治疗随机对照试验事后分析中的应用（NIDA-MDS-Modafinil-0001）
6. Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week Phase III Randomized Controlled Studies and One Long-Term Extension Study [O] . Alvin F. Wells, Bochao Jia, Li Xie, 2021

机译：长期治疗的功效与一次性类风湿性关节炎患者曾经 - 每日生长in 2毫克：后HOC分析24周第三期随机受控研究和一个长期扩展研究
7. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study [O] . Min-Chan Park, Hiroaki Matsuno, Jinseok Kim, 2019

机译：类风湿性关节炎患者继续对乙烯虫生物综合（LBEC0101）或从参考的替代赛转换为LBEC0101的长期疗效，安全性和免疫原性：III期多期一题，随机，双盲，并行组研究的开放标签延伸

Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study

著录项

相似文献

相关主题

期刊订阅